Pancreatic ductal adenocarcinoma (PDAC) is one of the most debilitating malignancies in humans, and one of the reasons for this is the inability to diagnose this disease early in its development. To search for biomarkers that can be used for early diagnosis of PDAC, we established a rat model of human PDAC in which expression of a human K-rasG12V oncogene and induction of PDAC are regulated by the Cre/lox system. In the present study, transgenic rats bearing PDAC and control transgenic rats with normal pancreatic tissues were used for metabolomic analysis of serum and pancreatic tissue by non-targeted and targeted gas chromatography-mass spectrometry and transcriptomic analysis of pancreatic tissue by microarray. Comparison of the metabolic profiles of the serum and pancreatic tissue of PDAC-bearing and control rats identified palmitoleic acid as a metabolite, which was significantly decreased in the serum of PDAC-bearing animals. Transcriptomic analysis indicated that several transcripts involved in anaerobic glycolysis and nucleotide degradation were increased and transcripts involved in the trichloroacetic acid cycle were decreased. Other transcripts that were changed in PDACbearing rats were adenosine triphosphate citrate lyase (decreased: fatty acid biosynthesis), fatty acid synthase (increased: fatty acid biosynthesis) and arachidonate 5-lipoxygenase activating protein (increased: arachidonic acid metabolism). Overall, our results suggest that the decreased serum levels of palmitoleic acid in rats with PDAC was likely due to its decrease in pancreatic tissue and that palmitoleic acid should be investigated in human samples to assess its diagnostic significance as a serum biomarker for human PDAC.
Introduction
Pancreatic cancer is diagnosed in ~1 person per 10 000 annually in the USA and is the fifth leading cause of cancer mortality. Most patients die within 1 year of diagnosis, and the 5 year survival rate, less than 5%, is dismal (1) . Pancreatic ductal adenocarcinomas (PDACs) are diagnosed in ≥95% of the patients with pancreatic cancer. The most widely used marker for pancreatic cancer, CA19-9, lacks specificity and sensitivity: it is elevated in cases of benign cholangitis and pancreatitis and also in other types of cancer, and it is not elevated during the early stages of PDAC, when the lesion is potentially curable (2-4).
Thus, there are presently no reliable biomarkers for the early detection of pancreatic cancer. Consequently, there is an urgent need for specific and sensitive biomarkers of pancreatic cancer.
Previously, we established transgenic rats in which expression of the human H-ras G12V or K-ras G12V oncogene is regulated by the Cre/lox system (5). Targeted activation of H-ras G12V or K-ras
G12V
is accomplished by injection of a Cre-carrying adenovirus into the pancreatic ducts through the common bile duct. Several weeks after injection, proliferative lesions in pancreatic duct epithelium, intercalated ducts and centroacinar cells, but not acinar cells, become widespread. The histopathological appearance of these adenocarcinomas closely resembles that described for typical pancreatic tumors in man. Thus, transgenic rats with induced PDACs in pancreatic tissues are an appropriate model for human PDAC. In this study, K-ras G12V transgenic rats (K-ras G12V Tg rats) were used because K-ras mutations are commonly observed in human PDAC.
Serum/plasma biomarkers are ideal in that the collection of samples is relatively non-invasive, and samples can be obtained repeatedly to monitor disease progression. Molecular profiling approaches such as transcriptomics, proteomics and metabolomics to monitor pathological processes of disease have received a great deal of attention. Metabolomic analysis refers to the comprehensive study of the many metabolites present in biological samples (6, 7) . The analytical techniques typically applied are nuclear magnetic resonance (8) and mass spectrometry (9) , with the latter being coupled to chromatographic separation techniques such as gas chromatography or liquid chromatography. Metabolomics is a powerful method for screening biomarkers, interpreting biological pathways and understanding functions of complex biological systems (10) . Recently, a urinary biomarker of prostate cancer aggressiveness was found using metabolomic profiling (11) .
In the present study, we characterized the metabolite profiles of both serum and pancreatic tissue samples from control and PDACbearing K-ras G12V Tg rats by non-targeted and targeted gas chromatography-mass spectrometry (GC-MS) analysis to identify potential serum biomarkers for the clinical diagnosis of PDAC. In addition, the metabolomic analysis was integrated with a transcriptomic analysis of pancreatic tissues to obtain a better understanding of the behavior of metabolites in PDAC. We identified palmitoleic acid as a metabolite that was significantly decreased in the serum of rats with PDAC, and integrated metabolomic and transcriptomic analyses suggest fluctuations in several metabolomic pathways in PDAC lesions.
Materials and methods

Ethics statement
All experiments were conducted in accordance with the 'Guidelines for Animal Experiments of Nagoya City University Graduate School of Medical Sciences', and the experimental protocol was approved by the Nagoya City University Medical School Institutional Animal Care and Use Committee.
Induction of pancreatic ductal adenocarcinoma
Kras301 rats conditionally expressing human K-ras G12V were generated as described previously (12) . An adenovirus vector carrying the Cre gene (AxCANCre) and an empty adenovirus vector (AxCAwt) were injected into the pancreatic ducts of 10-11-week-old adult homozygous male Kras301 rats through the common duct as described previously (5, 12) . Six rats were treated with AxCANCre (PDAC rats) and four with AxCAwt (as controls). All rats were maintained in plastic cages in an air-conditioned room with a 12 h light/12 h dark cycle and euthanized by blood withdrawal from the abdominal aorta under anesthesia 16-17 days after the injection of adenovirus vector.
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pathological examination (see below). Collected blood samples were allowed to clot at room temperature and then centrifuged at 3000 r.p.m. for 10 min at 4°C to obtain serum. The frozen pancreatic tissues and the serum were stored in liquid nitrogen and at −80°C, respectively, until metabolomic analysis.
Pathological examination
The remaining pancreatic tissues from PDAC and control rats were fixed in 4% paraformaldehyde, processed for embedding in paraffin, cut into 3 µm sections and stained with hematoxylin and eosin for microscopic examination.
RNA extraction from pancreatic tissues
Extraction of total RNA was performed using an RNeasy Mini Kit (Qiagen, Hilden, Germany). Quantification was performed with an Amersham Pharmacia spectrophotometer, model Ultraspec 3100pro (Amersham Pharmacia Biotech, Uppsala, Sweden), and assessment of ribosomal RNA integrity was performed using a 2100 Bioanalyzer (Agilent Technologies, Palo Alto, CA). Total RNA samples were stored at −80°C immediately after extraction.
Gene expression analysis
Gene expression levels were measured using a GeneChip System (Affymetrix, Santa Clara, CA). Reverse transcription of the extracted total RNA, secondstrand synthesis and probe generation were all accomplished with One-Cycle Target Labeling and Control Reagents (Affymetrix) following the manufacturer's protocol. Briefly, from 5 μg of total RNA, first-strand cDNA was synthesized with SuperScript II reverse transcriptase and a T7-oligo (dT) primer, and double-strand cDNA was synthesized with Escherichia coli RNase H, E.coli DNA polymerase I and E.coli DNA ligase. Biotin-labeled cRNA was prepared from the double-strand cDNA, and 15 μg of labeled cRNA was fragmented. Rat Genome 230 2.0 arrays were hybridized as described in the Gene Chip Expression Analysis Technical Manual (Affymetrix). The arrays were stained and washed with R-Phycoerythrin Streptavidin (Molecular Probes, Eugene, OR) and with the GeneChip Hybridization, Wash, and Stain Kit (Affymetrix). Fluorescence was intensified by the antibody-amplification method. The arrays were scanned with a GeneChip Scanner 3000 (Affymetrix) with Affymetrix Genechip Command Console (AGCC) and the image files were analyzed with an Affymetrix data suite system, Expression Console (EC) version 1.1; the tabdelimited files obtained contained data regarding the relative levels of expression of transcripts (signal) and the reliability of detection (Detection Call). The derived signal values were globally normalized to 100.
Sample preparation for GC-MS analysis
Pancreatic tissue and serum were subjected to two derivatization steps for GC-MS analysis. Pancreatic tissue samples (45-84 mg) were weighed and homogenized in a 12-fold volume solution of methanol/water/10 mM 2-hydroxyundecanoic acid (800:100:1, v/v/v; 10 mM 2-hydroxyundecanoic acid was used as an internal standard) using a potter homogenizer on ice, followed by centrifugation at 15 000 r.p.m. for 10 min at 4°C. Serum samples (50 μl) were deproteinized by addition of an 8-fold volume solution of methanol/water/10 mM 2-hydroxyundecanoic acid (800:100:1, v/v/v; 10 mM 2-hydroxyundecanoic acid was used as an internal standard), followed by centrifugation at 15 000 r.p.m. for 5 min at 4°C. The supernatant (200 μl) was dried in a vacuum freeze dryer, 30 μl of methoxylamine hydrochloride (Sigma-Aldrich) in pyridine (10 mg/ml) was added as a derivatizing agent and the mixture was incubated at 30°C for 90 min. Thereafter, 30 μl of N-methyl-N-(trimethylsilyl)trifluoroacetamide (GL Science, Tokyo, Japan) was added for derivatization, and the mixture was incubated at 40°C for 30 min.
GC-MS analysis
All analyses were carried out with a Bruker Daltonics1200 GC/MS/MS system (Bruker Daltonics K.K., Japan) using an Agilent Technologies VF5-ms capillary column (length, 30 m; internal diameter, 0.25 mm; film thickness, 0.25 μm). The injection temperature was 230°C. The helium gas flow rate through the column was 1 ml/min. The column oven temperature was 60°C for 2 min and rose at 10°C/min to 300°C and then remained at 300°C for 5 min. Ions were generated at an electron impact energy of 70 kV and were recorded over the mass range from m/z 70 to 800.
Analysis of GC-MS data
GC-MS data were imported into LineUp (Infometrix, Bothell, WA) and PiroTrans (GL Science) in order to align the chromatogram on the basis of peak intensity and the retention time of the internal standard, 2-hydroxyundecanoic acid. The generated peak lists were imported into Pirouette software (Infometrix, Woodinville, WA) for multivariate statistical analysis. Principal component analysis (PCA) was conducted to find discriminatory metabolites in serum and pancreatic tissues of PDAC rats. Identification of discriminatory metabolites detected by PCA analysis was performed using the NIST 05 Mass Spectral Library (NIST) containing >200 000 electron impact spectra.
In addition to the automatic library search assessment on the basis of similarity score (>65), the similarity of spectra was manually confirmed.
Identification and quantification of palmitoleic acid in pancreatic tissues
To authenticate the identity of the metabolite putatively identified as palmitelaidic acid, pancreatic tissues were analyzed by cochromatography with palmitelaidic acid and palmitoleic acid standards (MP Biomedicals, CA). The identity of the metabolite was determined based on comparison of the retention time and fragment pattern of the metabolite and those of the two standards.
For concentration measurements, palmitoleic acid was diluted in pyridine and six standards of various mixtures of compounds of known concentration between 0.05 and 100 p.p.m. were prepared. The concentration of palmitoleic acid in the samples was quantified by a standard curve of total ion current (TIC) chromatograms or m/z 311 mass chromatograms.
Statistics
The peak intensities of metabolites and the signal values of gene expression were statistically analyzed by the Student's t-test between PDAC and control rats, with a level of probability of 0.05 used as the criterion for significance.
Results
Gross and histological observation
Kras301 rats, 13-14 weeks of age, were killed 16-17 days after injection of adenovirus vector into the pancreatic duct via the common bile duct. Gross and histological findings were the same as reported previously (5, 12, 13) . PDAC was well developed with grossly visible whitish lesions in all six rats treated with AxCANCre. Histopathological examination showed that the tumors were adenocarcinomas with a variable amount of fibrotic tissue, some showing desmoplastic morphology and infiltration of inflammatory cells. Invasion of the surrounding normal pancreatic tissue by the PDAC that developed in Kras301 rats was a common feature of these lesions. Figure 1 shows typical lesions that developed in the Kras301 rats.
PDAC that develop in Kras301 rats are not metastatic, and neoplastic lesions were not found in any other organs. No abnormalities were observed in pancreatic tissues of the four rats injected with AxCAwt.
GC-MS chromatograms of serum and pancreatic tissues
Typical GC-MS TIC chromatograms of serum and pancreatic tissue extracts are shown in Supplementary Figure 1 , available at Carcinogenesis Online. The retention time of the internal standard was consistent for each run. The data showed marked differences in the chromatogram patterns between the serum and pancreatic tissue.
Clustering of control and PDAC samples
Score plots produced by PCA of the serum pancreatic tissue are shown in Figure 2 . The PCA algorithm generates a single point that represents the metabolites in a sample and their concentrations (each dot in the score plots shown in Figure 2 represents a single rat); close clustering of dots indicates that the samples have similar compositions. The control and PDAC samples clustered into two distinct groups in both the serum ( Figure 2A ) and pancreatic tissue ( Figure 2B ) score plots, indicating that the profiles of the metabolites in the serum and pancreatic tissue samples derived from the control rats differed from those derived from the rats with PDAC.
Metabolite differences between control and PDAC samples screened by PCA
In addition to the score plot, which is based on the composition of the samples, the PCA algorithm also creates a loading plot, which is based on metabolite values. Loading plots identify metabolites that contribute to the differential clustering of PDAC and control samples in the score plots. The electron impact spectra of these discriminatory metabolites were then compared with the NIST 05 Mass Spectral Library (NIST). Putatively identified discriminatory metabolites with matching NIST spectra are shown in Table I . Fold changes and P-values of these metabolites in the serum and pancreatic tissues were calculated by the TICs of GC-MS chromatograms.
In the serum, aminomalonic acid, 2-aminoethyl dihydrogen phosphate, citrate and lanthionine were significantly increased and chenodeoxycholic acid was non-significantly increased (1.9-fold). In pancreatic tissues, however, none of these metabolites was significantly increased and aminomalonic acid was significantly decreased.
A number of fatty acids were decreased in pancreatic tissues: palmitelaidic acid, linoleic acid, octadecanoic acid, myristic acid, arachidonic acid and hexadecanoic acid were significantly decreased and tridecanoic acid, 12-methyl-, methyl ester and heptadecanoic acid were non-significantly decreased. Of these fatty acids, only palmitelaidic acid (significantly decreased) and arachidonic acid (non-significantly decreased) were also decreased in the serum.
A third metabolite that had corresponding fluctuations in both the serum and pancreatic tissue was 2(1H)-pyrimidinone. This metabolite was significantly decreased in pancreatic tissues and non-significantly in the serum.
None of the other discriminatory metabolites had corresponding fluctuations in both the serum and pancreatic tissue. Beta-alanine, xanthine and uridine were increased in pancreatic tissue but not in the serum, and aspartic acid, alpha-glycerophosphoric acid, tyrosine, 2-monopalmitin, adenosine monophosphate and purine were decreased in pancreatic tissue but not in the serum.
Overall, the metabolic profiles in the pancreatic tissue and the serum of control and PDAC-bearing rats were different, with several discriminatory metabolites contributing to this difference. The array of changes in the individual discriminatory metabolites in the serum and pancreatic tissue, however, were distinct.
Identification and quantification of palmitoleic acid in pancreatic tissue and serum using standard chemicals
Once a metabolite that was significantly decreased in both pancreatic tissues and serum was detected and putatively identified as palmitelaidic acid, the identification of the metabolite was authenticated by cochromatography with palmitelaidic acid and palmitoleic acid. The retention time and fragment pattern of the standards identified the putatively annotated palmitelaidic acid as 'palmitoleic acid'.
A standard curve was then used for concentration measurement in samples: the linear region of quantitation was between 0.1 and 100 p.p.m. (R 2 = 0.9857). The concentrations of palmitoleic acid in pancreatic tissues and serum of the individual control and PDAC-bearing rats are shown in Table II . The palmitoleic acid concentration in the pancreatic tissues of control and PDAC rats was 266.5 186.2 and 7.5 4.6 p.p.m., respectively, and the concentration of palmitoleic acid in the serum samples of control and PDAC-bearing rats was 2.6 0.8 and 1.2 0.1 p.p.m., respectively (P-value: 0.031).
Alternations in the levels of metabolites involved in glycolysis and the trichloroacetic acid cycle
The 'Warburg effect' in which tumor cells rapidly use glucose and convert the majority of it to lactate is known as a typical signature of cancer (14, 15) . Since we observed decreases for a number of fatty acids, which are functionally related to the glycolytic pathway, in the pancreatic tissue of PDAC-bearing rats, we searched for peaks of metabolites involved in glycolysis and the trichloroacetic acid (TCA) cycle. Glucose, pyruvate, lactate, succinate, fumarate, malate and alph-keto-glutarate were identified. The changes in the levels of these metabolites in the serum and pancreatic tissues were calculated by the TICs of GC-MS chromatograms (Table III) . No significant differences between PDAC-bearing rats and control rats were found.
Transcriptional changes related to glycolysis, TCA cycle, fatty acid biosynthesis, arachidonic acid metabolism and nucleotide degradation Transcriptional data for ~31 000 genes in PDAC and control pancreatic tissue were analyzed by microarray; the genes for which significant changes (P ≤ 0.05) occurred are shown in Supplementary Table 1, available at Carcinogenesis Online. Values for enzymes involved in glycolysis, the TCA cycle, fatty acid biosynthesis, arachidonic acid metabolism and nucleotide degradation are shown in Table IV . Changes in Abat, Alox5, Dpyd, Dpys, Nt5, Uox and Upb transcription were evaluated as unclear as their expression levels were too low to be analyzed accurately by microarray analysis.
Pathways generated by integrating the results we obtained from our metabolic and transcriptional analyses are shown in Figure 3 . In PDAC lesions, numerous transcripts involved in anaerobic glycolysis were upregulated and most of those involved in the TCA cycle were downregulated ( Figure 3A) . Transcription of two lipogenic enzymes was also changed in PDAC lesions: adenosine triphosphate citrate lyase (Acly) was decreased and fatty acid synthase (Fasn) was increased ( Figure 3A) .
Transcripts of arachidonate 5-lipoxygenase activating protein (Alox5ap), which is necessary for activation of Alox5, were increased ( Figure 3B ). This increase may be associated with the decrease of linoleic acid and arachidonic acid found in the pancreatic tissue of PDAC-bearing rats (Table I) .
A number of transcripts involved in purine and pyrimidine nucleotide degradation were increased; however, transcripts involved in pyrimidine nucleotide degradation downstream of beta-alanine degradation were decreased ( Figure 3C ). Taken together, these changes may be associated with the changes of adenosine monophosphate, xanthine, uridine and beta-alanine found in pancreatic tissue of PDAC-bearing rats. Sera and pancreatic tissues from PDAC rats (n = 6) and controls (n = 4) were analyzed. ND, peaks were not detected. Metabolites that contributed to the differentiation of PDAC and control samples in the PCA analysis. *P < 0.05. Sera and pancreatic tissues from PDAC rats (n = 6) and controls (n = 4) were analyzed. ND, not detected. Pancreatic tissues derived from PDAC rats (n = 6) and controls (n = 4) were analyzed. P-values were calculated using Student's t-test.
Profiling of an animal model of pancreas cancer
a Expression levels were too low to be analyzed accurately by microarray analysis. *P < 0.05. 
Discussion
Serum metabolites are ideal biomarkers of human disease as the collection of serum samples is relatively non-invasive and multiple samples can be obtained to monitor disease progression. However, since serum represents the effects of metabolism in multiple organs, it is difficult to assign a metabolic fingerprint to specific metabolic processes of disease. Despite this, metabolites that change in the serum and display a similar change in diseased tissue, such as a cancerous lesion, are potential biomarkers specific to the metabolic process of the disease. In this study, sera and pancreatic tissues from four control and six PDAC rats were subjected to non-targeted and targeted GC-MS-based metabolomics. The PCA score plots of the non-targeted metabolomic data of both the serum and pancreatic tissue showed a clear separation between control and PDAC rats, indicating the presence of distinct metabolite profiles in the serum and pancreatic tissue of PDACbearing rats compared with control rats.
Palmitoleic acid, which contributed to the distinctive metabolic profiles of the samples from the PDAC-bearing and control rats, was significantly decreased in the serum. Palmitoleic acid is a monounsaturated fatty acid biosynthesized from palmitic acid. Since palmitoleic acid is also contained in the diet, the decreases in the serum and pancreatic tissue of PDAC-bearing rats could be due to decreased absorption from the intestine. However, the decrease in PDAC-bearing rat lesions was apparently more pronounced in pancreatic tissue than in the serum. If the decrease in palmitoleic acid in the pancreatic tissue was due to its decreased levels in the serum, then the decreases found in the serum and pancreatic tissue should be similar. Instead, palmitoleic acid was decreased by a factor of ~2 in the serum and by a factor of ~7 or more in pancreatic tissue: while the decrease in palmitoleic acid in the pancreatic tissue of PDAC-bearing animals was not statistically different from the controls, it is notable that the highest level of palmitoleic acid in the PDAC rats was 13.77 p.p.m., whereas the lowest level of palmitoleic acid in the control rats was 100.33 p.p.m., a 7-fold difference. This suggests that decreased palmitoleic acid in pancreatic tissue was most likely due to increased consumption of the fatty acid in the PDAC lesions and that the decrease of palmitoleic acid in the serum was likely caused by its decrease in pancreatic tissues. Therefore, palmitoleic acid in the serum is a candidate biomarker for PDAC diagnosis.
In addition to palmitoleic acid, two other metabolites showed decreases in both the serum and pancreatic tissue: Arachidonic acid and 2(1H)-pyrimidinone were decreased non-significantly in the serum and decreased significantly in pancreatic tissue samples. Interestingly, the decrease of arachidonic acid could have been mediated by the increased expression of Alox5ap in PDAC (see Figure 3B ). Increased activation of Alox5 could be the cause of the decrease of linoleic acid and arachidonic acid in the pancreatic tissue of PDAC-bearing rats. However, further investigations are needed to ascertain whether decreased linoleic acid and arachidonic acid were due to aberrant arachidonic acid metabolism or decreased synthesis of fatty acids.
One of the hallmarks of cancer is an increase of de novo fatty acid synthesis (16) . A wide variety of tumors and their precursor lesions undergo exacerbated de novo biosynthesis of fatty acids from citrate by lipogenic enzymes-Acly, acetyl-CoA carboxylase and Fasn-irrespective of the levels of circulating lipids (16) . In our study, however, we detected a decrease in the levels of several fatty acids. Possibly, decreased Acly expression (see Figure 3A) may have caused the decreases seen in the fatty acids in the pancreatic tissue of PDAC-bearing rats.
Another hallmark of cancer is the 'Warburg effect' (14, 15) and decreased glucose has been reported in the serum and cancerous tissues of oral, colon and stomach cancer patients (17, 18) and increased lactate has been reported in the serum of pancreatic cancer patients (19) . In the present study, transcriptional analysis of PDAC tissues also suggested activation of anaerobic glycolysis and suppression of the TCA cycle. However, neither decreased glucose nor increased lactate were observed in the serum or pancreatic tissue of PDAC-bearing rats. The lack of a 'Warburg effect' in PDAC-bearing rats was probably due to the fact that after ~2 weeks of development, the PDACs were not advanced enough to disrupt pancreatic function and glucose control.
A notable difference between palmitoleic acid and glucose and lactic acid is that there are metabolic pathways dedicated to the regulation of glucose and lactic acid levels, but not to palmitoleic acid levels. Consequently, the tumor-mediated fluctuations in glucose and lactic acid seen in patients with more advanced tumors (17-19) may be absent in patients (and animal models) with less advanced tumors. In contrast, fluctuations of unregulated metabolites, such as palmitoleic acid, may occur in patients (and animal models) with less advanced tumors, as seen in the present study.
The increase in nucleotide degradation products xanthine, uridine and beta-alanine coupled with increased expression of several enzymes involved in nucleotide degradation (see Figure 3C ) suggests that accelerated nucleotide degradation is occurring in the PDAC lesions. This accelerated nucleotide degradation may be due to the increased turnover of nucleotides in the PDAC lesions, which results from the increased nucleic acid synthesis in proliferating cells in the lesions.
Chenodeoxycholic acid, a major constituent of bile acids, was increased in the serum of PDAC-bearing rats. Metabolomic profiling of plasma of pancreas cancer patients by Urayama et al. (20) also showed an elevation of the bile acids taurocholic acid and tauroursodeoxycholic acid.
Concluding remarks
In summary, metabolites in the serum and pancreatic tissue of control and PDAC-bearing K-ras G12V transgenic rats were analyzed by non-targeted and targeted GC-MS and transcripts in the PDAC lesions were analyzed by microarray. GC-MS analysis indicated that the profiles of the metabolites in the serum and pancreatic tissue samples derived from control rats differed from those derived from PDACbearing rats. A metabolite identified as palmitoleic acid was significantly decreased in the serum of PDAC-bearing rats and this decrease was likely due to its decrease in pancreatic tissue. Two other interesting metabolites are linoleic acid and arachidonic acid. These metabolites were significantly decreased in the pancreases of PDAC-bearing rats, possibly due to Alox5ap-mediated upregulation of Aox5 activity. Whether these metabolites could be markers of more advanced pancreas cancer remains to be determined. Finally, integration of the results of the non-targeted GC-MS analysis and transcriptomic Fig. 3 . Schematic representations of the most relevant metabolic and transcriptional differences in pancreatic tissues between PDAC and normal rats. Red, higher concentration in PDAC rats. Blue, lower concentration in PDAC rats. Black, not changed. Gray, not determined or unclear. 1 Pfkp was increased, whereas Pfkm was decreased.
2 Idh3a was increased, whereas Idh2, Idh3B and Idh3g were decreased.
